Product
Trastuzumab Pyrotinib Exemestane Dalpiciclib
1 clinical trial
3 indications
Indication
Breast CancerIndication
Estrogen Receptor Positive TumorIndication
Breast Cancer (HER2-positive)Clinical trial
Phase II Open-label, Multicentre, Exploratory Trial of Neoadjuvant Dalpiciclib in Combination With Exemestane and Trastuzumab Plus Pyrotinib in Early Triple Positive Breast CancerStatus: Recruiting, Estimated PCD: 2024-12-01